Exelixis Inc at Stifel Healthcare Conference (Virtual) Transcript
All right. Good afternoon, everyone. I'm Stephen Willey, one of the senior biotech analysts here at Stifel. I'm glad to have with us to close out the day, Exelixis, represented by Chris Senner, who is the Chief Financial Officer; and Andrew Peters, who heads up their business development efforts. I think normally, I would ask companies to make an opening statement with respect to who they are, what they do, but I'm pretty sure everyone knows who Exelixis is and what Exelixis does.
Questions & Answers
So maybe we can just kind of get right into the discussion here and start off by talking about the cabo launch into front-line RCC. I know that we're coming off sequentially down 3Q in terms of net sales. I know that demand metrics looked pretty strong. And obviously, your guidance suggests that that's not going to be the case again in 4Q. But what's your level
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
